Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Receptors, Estrogen

abstract

  • Among patients with node-positive tumors, ER-negative breast cancer, biweekly doxorubicin/cyclophosphamide plus paclitaxel lowers the rate of recurrence and death by more than 50% in comparison with low-dose cyclophosphamide, doxorubicin, and fluorouracil as used in the first study.

publication date

  • April 12, 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC1459540

Digital Object Identifier (DOI)

  • 10.1001/jama.295.14.1658

PubMed ID

  • 16609087

Additional Document Info

start page

  • 1658

end page

  • 67

volume

  • 295

number

  • 14